tbuckley/cabot-search huggingface dataset:
Transluminal coronary angioplasty
Authors: C. J. Pepine
Journal: JAMA (1980)

TRANSLUMINAL coronary angioplasty is a new alternative approach to the treatment of coronary artery disease in which a narrowed coronary artery is enlarged by a special balloon catheter introduced through a peripheral artery. The technique's background is derived from nonsurgical catheter treatment of peripheral vascular disease that was first introduced by Dotter and Judkins<sup>1</sup>in 1964. Their technique used progressively larger catheters to dilate atherosclerotic peripheral vascular lesions, but the technique remained controversial. Failure of this technique to gain widespread acceptance was thought to relate to its causing endothelial damage that led to possible peripheral emboli or occlusion in many cases. Convinced that the contents of atheromatous lesions were capable of "compression remodeling" by forcing material outward toward the arterial wall, Dotter and his co-workers<sup>2</sup>suggested the rational basis for this nonsurgical form of therapy. They also recognized that an expansile balloon-type catheter dilator could be more useful
Mid-(4-month) and long-term (1-year) QCA and three-dimensional IVUS follow-up after implantation of sirolimus-coated stent in human coronary arteries J. Eduardo M. R. Sousa, Marco A. Costa, Alexandre Abizaid, Andrea S. Abizaid, Fausto Feres, Ibraim M.F. Pinto, Ana C. Seixas, Galo Maldonato, Luiz A. Mattos, Amanda G. M.R. Sousa, Robert Falotico, Judith Jaeger, Jeffrey J. Popma, Patrick W. Serruys. Institute Dante Pazzanese of Cardiology, S�o Paulo, Brazil
Journal: Journal of the American College of Cardiology (2001)
Error in Figure 1
Authors: Ezra Golberstein
Journal: JAMA Pediatrics (2020)

Saara Lehtiranta, MD; Minna Honkila, MD, PhD; Merja Kallio, MD, PhD; Niko Paalanne, MD, PhD; Outi Peltoniemi, MD, PhD; Tytti Pokka, MSc; Marjo Renko, MD, PhD; Terhi Tapiainen, MD, PhD
Insulin signaling in health and disease
Authors: Alan R. Saltiel
Journal: Journal of Clinical Investigation (2021)

The molecular mechanisms of cellular insulin action have been the focus of much investigation since the discovery of the hormone 100 years ago. Insulin action is impaired in metabolic syndrome, a condition known as insulin resistance. The actions of the hormone are initiated by binding to its receptor on the surface of target cells. The receptor is an α2β2 heterodimer that binds to insulin with high affinity, resulting in the activation of its tyrosine kinase activity. Once activated, the receptor can phosphorylate a number of intracellular substrates that initiate discrete signaling pathways. The tyrosine phosphorylation of some substrates activates phosphatidylinositol-3-kinase (PI3K), which produces polyphosphoinositides that interact with protein kinases, leading to activation of the kinase Akt. Phosphorylation of Shc leads to activation of the Ras/MAP kinase pathway. Phosphorylation of SH2B2 and of Cbl initiates activation of G proteins such as TC10. Activation of Akt and other protein kinases produces phosphorylation of a variety of substrates, including transcription factors, GTPase-activating proteins, and other kinases that control key metabolic events. Among the cellular processes controlled by insulin are vesicle trafficking, activities of metabolic enzymes, transcriptional factors, and degradation of insulin itself. Together these complex processes are coordinated to ensure glucose homeostasis.
Interleukin-1β secretion induced by mucosa-associated gut commensal bacteria promotes intestinal barrier repair
Authors: Wan-Jung H. Wu, Myunghoo Kim, Lin-Chun Chang, Adrien Assie, Fatima B. Saldana-Morales, Daniel F. Zegarra-Ruiz, Kendra Norwood, Buck S. Samuel, Gretchen E. Diehl
Journal: Gut Microbes (2022)

The gut microbiota is essential for maintenance and repair of the intestinal epithelial barrier. As shifts in both intestinal epithelial barrier function and microbiota composition are found in inflammatory bowel disease patients, it is critical to understand the role of distinct bacteria in regulating barrier repair. We identified a mouse commensal E. coli isolate, GDAR2-2, that protects mice from Citrobacter rodentium infection and dextran sulfate sodium-induced colitis. Colonization with GDAR2-2 in mice resulted in expansion of CX3CR1+ mononuclear phagocytes, including CX3CR1+ macrophages/dendritic cells and monocytes, along with IL-22-secreting type 3 innate lymphoid cells and improved epithelial barrier function. In vitro co-culture of macrophages with GDAR2-2 resulted in IL-1β production. In vivo, protection after GDAR2-2 colonization was lost after depletion of CX3CR1+ MNPs, or blockade of IL-1β or IL-22. We further identified human commensal E. coli isolates that similarly protect mice from C. rodentium infection through CX3CR1+ MNP and IL-1β production. Together, these findings demonstrate an unexpected role for commensal bacteria in promoting IL-1β secretion to support intestinal barrier repair.
Drug discovery of sclerostin inhibitors
Authors: Sifan Yu, Dijie Li, Ning Zhang, Shuaijian Ni, Meiheng Sun, Luyao Wang, Huan Xiao, Dingdong Liu, Jin Liu, Yuanyuan Yu, Zongkang Zhang, Samuel Tin Yui Yeung, Shu Zhang, Aiping Lu, Zhenlin Zhang, Baoting Zhang, Ge Zhang
Journal: Acta Pharmaceutica Sinica B (2022)

Sclerostin, a protein secreted from osteocytes, negatively regulates the WNT signaling pathway by binding to the LRP5/6 co-receptors and further inhibits bone formation and promotes bone resorption. Sclerostin contributes to musculoskeletal system-related diseases, making it a promising therapeutic target for the treatment of WNT-related bone diseases. Additionally, emerging evidence indicates that sclerostin contributes to the development of cancers, obesity, and diabetes, suggesting that it may be a promising therapeutic target for these diseases. Notably, cardiovascular diseases are related to the protective role of sclerostin. In this review, we summarize three distinct types of inhibitors targeting sclerostin, monoclonal antibodies, aptamers, and small-molecule inhibitors, from which monoclonal antibodies have been developed. As the first-in-class sclerostin inhibitor approved by the U.S. FDA, the monoclonal antibody romosozumab has demonstrated excellent effectiveness in the treatment of postmenopausal osteoporosis; however, it conferred high cardiovascular risk in clinical trials. Furthermore, romosozumab could only be administered by injection, which may cause compliance issues for patients who prefer oral therapy. Considering these above safety and compliance concerns, we therefore present relevant discussion and offer perspectives on the development of next-generation sclerostin inhibitors by following several ways, such as concomitant medication, artificial intelligence-based strategy, druggable modification, and bispecific inhibitors strategy.
Patterns in Prior antiplatelet therapy and impact on outcome in patients with ACS. Results from the global registry of acute coronary events Frederick Spencer, Joel M. Gore, Robert J. Goldberg, Keith A.A. Fox, Mauro Moscucci, Cynthia M. Sullivan, Kami White, Enrique Gurfinkel, for the GRACE Investigators. University of Massachusetts Medical School, Worcester, MA, Buenos Aires University, Buenos Aires, Argentina
Journal: Journal of the American College of Cardiology (2001)
Middle East Coronavirus Infections Surpass 100; Fatality Rate is 45%
Journal: JAMA (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Long-term clinical and hemodynamic outcome after percutaneous septal ablation for hypertrophic obstructive cardiomyopathy Leon Krater, Hubert Seggewiss, Axel Meissner, Lothar Faber, Dieter Horskotte. Heart Center North Rhine-Westphalia, Bad Oeynhausen, Germany, Leopoldina Hospital, Schweinfurt, Germany
Journal: Journal of the American College of Cardiology (2001)
The Diagnosis of Surgical Diseases.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The state medical association and continuing medical education
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Baseline and serial neurohormones in patients with congestive heart failure treated with and without bucindolol: Results of the neurohumoral substudy of the beta-blocker evaluation of survival trial (BEST) Robert P. Frantz, Brian Lowes, Paul Grayburn, Michel White, Edward M. Gilbert, Heidi Krause-Steinrauf, John C. Burnett, for the BEST Investigators. Mayo Clinic and Mayo Foundation, Rochester, MN, University of Colorado Medical Center, Denver, CO
Journal: Journal of the American College of Cardiology (2001)
USE AND ABUSE OF COCAIN.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management
Authors: Mrinal M. Patnaik, Ayalew Tefferi
Journal: American Journal of Hematology (2022)

Abstract Disease Overview Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder with overlapping features of myelodysplastic syndromes and myeloproliferative neoplasms, with an inherent risk for leukemic transformation (~15% over 3–5 years). Diagnosis Diagnosis is based on the presence of sustained (&gt;3 months) peripheral blood monocytosis (≥1 × 10 9 /L; monocytes ≥10%), usually with accompanying bone marrow dysplasia. Clonal cytogenetic abnormalities occur in ~30% of patients, while &gt;90% have somatic gene mutations. Mutations involving TET2 (~60%), SRSF2 (~50%), ASXL1 (~40%), and the oncogenic RAS pathway (~30%) are frequent, while the presence of ASXL1 and DNMT3A mutations and the absence of TET2 mutations negatively impact overall survival. Risk‐Stratification Molecularly integrated prognostic models include the Groupe Français des Myélodysplasies, Mayo Molecular Model (MMM), and the CMML specific prognostic model. Risk factors incorporated into the MMM include presence of truncating ASXL1 mutations, absolute monocyte count &gt;10 × 10 9 /L, hemoglobin &lt;10 g/dL, platelet count &lt;100 × 10 9 /L, and the presence of circulating immature myeloid cells. The MMM stratifies CMML patients into four groups: high (≥3 risk factors), intermediate‐2 (2 risk factors), intermediate‐1 (1 risk factor), and low (no risk factors), with median survivals of 16, 31, 59, and 97 months, respectively. Risk‐adapted therapy Hypomethylating agents such as 5‐azacitidine and decitabine are commonly used, with overall response rates of ~40%–50% and complete remission rates of ~7%–17%; with no impact on mutational allele burdens. Allogeneic stem cell transplant is the only potentially curative option but is associated with significant morbidity and mortality.
Correction:<i>MRI of tumor T cell infiltration in response to checkpoint inhibitor therapy</i>
Authors: Mehmet Altan, Fangxin Hong, John V Heymach, Elizabeth Jiménez-Aguilar, Zihan Wei, Andrew J Plodkowski, Peter Sawan, Jia Luo, Hira Rizvi, Brett W Carter
Journal: Journal for ImmunoTherapy of Cancer (2020)
Abstract 17042: Ketone Body Utilization is Suppressed in Patients With Ischemic Heart Disease
Authors: Yuichiro Arima, Yasuhiro Izumiya, Toshifumi Ishida, Seiji Takashio, Masanobu Ishii, Daisuke Sueta, Eiichiro Yamamoto, Kenji Sakamoto, Hisanori Kanazawa, Koichiro Fujisue, Satoshi Araki, Shinsuke Hanatani, Hiroshige Yamabe, Koichi Kaikita, Kenichi Tsujita
Journal: Circulation (2018)

Introduction: Ketone bodies (acetoacetate, acetone, and β-hydroxybutyrate [βOHB]) are well-known energy substrates. Recent reports revealed that heart failure augmented the utilization of ketone bodies. However, little is known about the effects of an ischemic condition on the utilization of ketone bodies. Hypothesis: Myocardial ischemia suppresses ketone body utilization. Methods: We retrospectively enrolled 171 consecutive patients who were planned to undergo acetylcholine (ACh) provocation test. Lactate and βOHB concentrations at the aortic root and coronary sinus were simultaneously measured. Coronary lactate production (CLP) was defined lactate concentration at the coronary sinus was greater than that in the aortic root and indicated enhancement of anaerobic metabolism. Subjects were divided into two groups according to the CLP at baseline (CLP (+): n=32, CLP (-): n=121). Subsequently, to assess the acute effect of myocaridal ischemia, subjects of CLP (-) at baseline were further grouped into two groups according to CLP after ACh provocation test (Provoked-CLP (+), n=81; Provoked-CLP (-), n=40). βOHB extraction rate as follows; {[Concentration at aortic root]-[Concentration at coronary sinus or femoral vein]}/ [Concentration at aortic root] х 100. Results: Concentration of βOHB at the aortic root, femoral vein and coronary sinus was significantly higher in patients with CLP (+) than CLP(-) at baseline [129-494 (226) vs 43-236 (105) μmol/L, p=0.0003; 58-412 (131) vs 27-163 (53) μmol/L, p=0.0004; 74-323 (149) vs 26-158 (63) μmol/L, p&lt;0.0001, respectively]. CLP at baseline was related to a decreased coronary βOHB extraction rate [CLP (+): 23.8-33.7% (29.9%) , CLP (-): 33.2-44.0% (38.5%)]. Conclusions: Concentrations of βOHB were elevated in patients with myocaridal ischemia. βOHB extraction rate in the coronary circulation was suppressed by acute and chronic ischemic stresses.
Errors in Abstract, Text, and Supplement
Authors: Hsien-Ho Lin
Journal: JAMA Internal Medicine (2020)

Hao-Yuan Cheng, MD, MSc; Shu-Wan Jian, DVM, MPH; Ding-Ping Liu, PhD; Ta-Chou Ng, BSc; Wan-Ting Huang, MD; Hsien-Ho Lin, MD, ScD; for the Taiwan COVID-19 Outbreak Investigation Team
The Lamentation of Mary Over the Body of Christ With Angels Holding the Symbols of the Passion
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Serotonin And Vascular Responses
Authors: N. Hollenberg
Journal: The Annual Review of Pharmacology and Toxicology (1988)

Over the past two decades, deadly coronaviruses, with the most recent being the severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) 2019 pandemic, have majorly challenged public health. The path for virus invasion into humans and other ...Read More
Cytomegalovirus hyperimmunoglobulin treatment in cytomegalovirus myocarditis and its influence on serum titers of cardiotropic viruses Bernhard Maisch, G�nther Hufnagel, Sabine Pankuweit. Department of Internal Medicine-Cardiology, Philipps University, Marburg, Germany
Journal: Journal of the American College of Cardiology (2001)
Osteomyelitis
Authors: A E Glatt
Journal: New England Journal of Medicine (1997)

To the Editor: Ridker and colleagues (April 3 issue) 1 have provided important new information that will be useful in assessing the risk of cardiovascular events and in optimizing prophylaxis.Both Ridker et al. and Maseri, in his editorial, 2 speculate that the antiinflammatory effects of aspirin may be important in reducing the risk of myocardial infarction when the level of C-reactive protein is high.It seems unlikely that the antiinflammatory effects of aspirin have an important role, since these effects are minuscule and short-lived at the dosage used in the study by Ridker et al. (325 mg every other day).Were these effects of aspirin indeed important, higher doses would be expected to confer a greater cardioprotective effect.I am not aware of any controlled study that has demonstrated a greater effect with higher doses.An alternative possibility is that an elevated level of C-reactive protein is associated with increased coagulability (local or systemic, or both) and that the cardioprotective effects of aspirin are proportional to the magnitude of this increase in coagulability.
Targeting Squalene Epoxidase Interrupts Homologous Recombination via the ER Stress Response and Promotes Radiotherapy Efficacy
Authors: Zhipeng Hong, Tao Liu, Lingfeng Wan, Pengyan Fa, Pankaj Kumar, Yanan Cao, Chandra Bhushan Prasad, Zhaojun Qiu, Joseph Liu, Hongbing Wang, Zaibo Li, Qi-En Wang, Peixuan Guo, Deliang Guo, Ayse S. Yilmaz, Lanchun Lu, Ioanna Papandreou, Naduparambil K. Jacob, Chunhong Yan, Xiaoli Zhang, Qing-Bai She, Zhefu Ma, Junran Zhang
Journal: Cancer Research (2022)

Abstract Over 50% of all patients with cancer are treated with radiotherapy. However, radiotherapy is often insufficient as a monotherapy and requires a nontoxic radiosensitizer. Squalene epoxidase (SQLE) controls cholesterol biosynthesis by converting squalene to 2,3-oxidosqualene. Given that SQLE is frequently overexpressed in human cancer, this study investigated the importance of SQLE in breast cancer and non–small cell lung cancer (NSCLC), two cancers often treated with radiotherapy. SQLE-positive IHC staining was observed in 68% of breast cancer and 56% of NSCLC specimens versus 15% and 25% in normal breast and lung tissue, respectively. Importantly, SQLE expression was an independent predictor of poor prognosis, and pharmacologic inhibition of SQLE enhanced breast and lung cancer cell radiosensitivity. In addition, SQLE inhibition enhanced sensitivity to PARP inhibition. Inhibition of SQLE interrupted homologous recombination by suppressing ataxia-telangiectasia mutated (ATM) activity via the translational upregulation of wild-type p53-induced phosphatase (WIP1), regardless of the p53 status. SQLE inhibition and subsequent squalene accumulation promoted this upregulation by triggering the endoplasmic reticulum (ER) stress response. Collectively, these results identify a novel tumor-specific radiosensitizer by revealing unrecognized cross-talk between squalene metabolites, ER stress, and the DNA damage response. Although SQLE inhibitors have been used as antifungal agents in the clinic, they have not yet been used as antitumor agents. Repurposing existing SQLE-inhibiting drugs may provide new cancer treatments. Significance: Squalene epoxidase inhibitors are novel tumor-specific radiosensitizers that promote ER stress and suppress homologous recombination, providing a new potential therapeutic approach to enhance radiotherapy efficacy.